Universal Beteiligungs und Servicegesellschaft mbH Purchases New Shares in 10x Genomics $TXG

Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of 10x Genomics (NASDAQ:TXG) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 100,882 shares of the company’s stock, valued at approximately $1,179,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.08% of 10x Genomics as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in TXG. Royal Bank of Canada lifted its holdings in shares of 10x Genomics by 806.4% in the 1st quarter. Royal Bank of Canada now owns 182,836 shares of the company’s stock valued at $1,597,000 after acquiring an additional 162,665 shares during the last quarter. Goldman Sachs Group Inc. raised its position in 10x Genomics by 163.5% during the first quarter. Goldman Sachs Group Inc. now owns 645,366 shares of the company’s stock valued at $5,634,000 after purchasing an additional 400,430 shares during the period. Focus Partners Wealth purchased a new stake in 10x Genomics during the first quarter valued at approximately $92,000. Public Employees Retirement System of Ohio raised its position in 10x Genomics by 210.1% during the second quarter. Public Employees Retirement System of Ohio now owns 100,636 shares of the company’s stock valued at $1,165,000 after purchasing an additional 68,182 shares during the period. Finally, Venturi Wealth Management LLC bought a new stake in shares of 10x Genomics in the 2nd quarter valued at approximately $208,000. 84.68% of the stock is currently owned by institutional investors.

10x Genomics Price Performance

TXG stock opened at $20.20 on Friday. 10x Genomics has a 12 month low of $6.78 and a 12 month high of $23.56. The firm’s 50-day moving average is $18.64 and its 200 day moving average is $15.22. The company has a market capitalization of $2.56 billion, a PE ratio of -32.58 and a beta of 2.18.

10x Genomics (NASDAQ:TXG) last issued its earnings results on Thursday, November 6th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.05. 10x Genomics had a negative net margin of 11.89% and a negative return on equity of 11.50%. The business had revenue of $149.00 million for the quarter, compared to the consensus estimate of $142.50 million. During the same period in the prior year, the firm earned ($0.30) EPS. The company’s revenue for the quarter was down 1.7% compared to the same quarter last year. Sell-side analysts forecast that 10x Genomics will post -1.43 EPS for the current fiscal year.

Insiders Place Their Bets

In other 10x Genomics news, insider Benjamin J. Hindson sold 8,283 shares of 10x Genomics stock in a transaction on Monday, November 24th. The stock was sold at an average price of $19.00, for a total transaction of $157,377.00. Following the completion of the sale, the insider directly owned 432,605 shares of the company’s stock, valued at $8,219,495. The trade was a 1.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Serge Saxonov sold 13,261 shares of the company’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $19.00, for a total value of $251,959.00. Following the completion of the sale, the chief executive officer owned 1,021,556 shares of the company’s stock, valued at $19,409,564. This represents a 1.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 33,432 shares of company stock worth $635,208 in the last ninety days. 9.39% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Barclays increased their price target on 10x Genomics from $17.00 to $22.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Citigroup downgraded shares of 10x Genomics from a “buy” rating to a “cautious” rating in a research note on Thursday, December 11th. TD Cowen reaffirmed a “hold” rating on shares of 10x Genomics in a research note on Wednesday, January 7th. Morgan Stanley reiterated an “equal weight” rating and set a $20.00 price target (up from $17.00) on shares of 10x Genomics in a report on Monday, December 1st. Finally, Canaccord Genuity Group raised their price objective on shares of 10x Genomics from $19.00 to $20.00 and gave the stock a “buy” rating in a research note on Monday, December 22nd. Four research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $16.83.

About 10x Genomics

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.